Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People with Type 2 Diabetes

Rosalie A. Scholtes, Anne C. Hesp, Charlotte M. Mosterd, Frank Geurts, Ewout J. Hoorn, Daan J. Touw, Merle M. Krebber, Jaap A. Joles, Hiddo J.L. Heerspink, Daniël H. Van Raalte*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1895-1897
Number of pages3
Issue number24
Publication statusPublished - 13 Dec 2022

Bibliographical note

Sources of Funding:
Boehringer Ingelheim provided the empagliflozin and empagliflozin-placebo tablets.

Cite this